VeriMom¿Debo evitar minoxidil succinoyl oligopeptide-143 durante el embarazo? | VeriMom
Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- ¿Es minoxidil succinoyl oligopeptide-143 seguro durante el embarazo?
- Minoxidil (6-(piperidinyl)-2,4-pyrimidinediamine-3-oxide) is listed as a substance that must not form part of the composition of cosmetics in EU Annexes (minoxidil and its salts appear in the prohibited list), which by your rules requires h≥2. Topical minoxidil is systemically absorbed in measurable amounts and there are case reports of effects in infants after dermal exposure; therefore a mechanism of systemic exposure is plausible. No SCCS/CIR opinion or harmonised H360/H361 specific to the peptide was found; evidence is via minoxidil data and regulatory prohibition. Sources: EU Annex listing, PubChem/minoxidil, EMA safety note on infant hypertrichosis.
- ¿Es minoxidil succinoyl oligopeptide-143 seguro durante la lactancia?
- Minoxidil is a pharmacologically active systemic agent with reports of infant effects after maternal topical use and some evidence of transmission/infant exposure; regulatory guidance warns about infant hypertrichosis following skin contact. Thus breastfeeding safety is a concern (h=2). Mechanistic concern is demonstrated systemic exposure; measured transfer into milk is not well-quantified in public cosmetic dossiers, so exposure is graded as low but measurable for breastfeeding (e=1).
- ¿Es minoxidil succinoyl oligopeptide-143 seguro para la piel del bebé?
- For dermal contact with infants (0–3 yr) there are case reports of excessive hair growth in infants after parental topical minoxidil use/contact, and infants have higher dermal uptake (immature barrier and higher surface-area-to-weight). Therefore hazard and mechanism scores follow minoxidil (h=2, m=2) and exposure is increased (adult e=2 → infant e=3 per your rules). No infant-specific toxicology studies for the peptide were found; the concern is driven by the minoxidil parent compound and case reports.
- ¿Cómo puntúa VeriMom a minoxidil succinoyl oligopeptide-143?
- VeriMom puntúa minoxidil succinoyl oligopeptide-143 en 33/100 (riesgo alto) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a minoxidil succinoyl oligopeptide-143 en el embarazo?
- Consulta nuestra lista de alternativas seguras a minoxidil succinoyl oligopeptide-143 según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.